The eightieth annual meeting of the American Association for Cancer Research was held on May 24 to 27, 1989, in San Francisco. This annual meeting continues to attract an increasing number of participants, with over two thousand abstracts and several major lectures presented during the four days. The scope of the meeting reflected the broad research interests of the association, and included sessions on cancer biology, biochemistry and molecular biology, carcinogenesis and epidemiology, endocrinology and immunology, and experimental therapeutics, preclinical pharmacology and clinical investigations. The meeting concluded with three methods workshops: cloning, expressing, and modifying genes; transgenic mice as a model for oncogenesis; and the polymerase chain reaction, its subleties and application. The importance of these techniques in molecular biology to the future of cancer research was clearly evident by the interest in these workshops.
This theme was the basis of the presidential address of Dr. Lawrence Loeb, "Molecular Oncology into the 21 st Century". The impact of molecular biology methodologies will be substantial, according to Dr. Loeb, leading to advances in defining the interactions of macromoloecules at the atomic level, and the ability to discern critical genetic alterations that cause, promote, and establish the malignant phenotype. Molecular approaches to oncology will extend other areas of cancer research as well: epidemiologists will quantitate the accumulation of DNA adducts and correlate genetic changes with environmental exposures; geneticists will relate DNA repair defects, with a proclivity for cancer; diagnosticians will have a library of genetic indicators for predicting tumor behaviour; and chemotherapists will be presented with new target genes and approaches to the design of specific agents to control the malignant phenotype of tumor cells.
Understanding of the etiology of cancer is one area where molecular oncology has produced spectacular results. In the Clowes Memorial Award Lecture, Dr. Janet Rowley described cytogenetic studies demonstrating that chromosome abnormalities in cancer were nonrandom and showed specificity for specific tumor types. For example, a 15;17 translocation was observed in all 57 cases of acute promyelocytic leukemia studied, but was not observed in any other tumor type. The Philadelphia chromosome (Phi), found in CML, has been shown to be a translocation between chromosomes 9 and 22. Cloning studies demonstrated that the oncogene abl is translocated from chromosome 9 into a gene on chromosome 22 designated bcr. The abl-bcr fusion gene produces a 8.5 kb fusion mRNA and a 210 kDa fusion protein with a higher level of tyrosine protein kinase activity than the normal 140 kDa protein. A similar 9;22 translocation is also found in approximately 15 % of acute lymphocytic leukemia (ALL) patients. In these cases, the breakpoint in the abl gene was the same in the CML and ALL patients. However in half of the ALL patients, a different breakpoint in the bcr gene was found, with a consequent smaller fusion protein of 190 kDa. The biological and clinical consequences of this translocation are now being studied. Information about genetic abnormalities has immediate clinical importance as well. For example by using probes for the junction of the fusion genes in combination with the polymerase chain reaction, the presence of one Ph 1 leukemia cell in 106 normal cells can be detected, leading to the identification of leukemia in tissues otherwise thought to be disease-free.
Important advances in the understanding of the genetic etiology of colon cancer were described by Dr. Bert Vogelstein in the Rhoads Memorial lecture. Among the chromosomal alterations identified to date are: alMic deletion of chromosome 5q, which is linked to the gene for familial adenomatous polyposis and occurs early in tumor progression in 35% of biopsies examined; mutations in codon 12 and 13 of the K-ras oncogene, which was observed in 50% of tumors and appears to be an intermediate change (i.e. arising during the growth of a small benign adenoma into a more advanced tumor); and deletions of small regions of chromosomes 17p and 18q, which were observed in over 75% of colon carcinomas and are a late occuring event. These latter two deletions were further found to be strongly correlated with distant metastasis and cancer-related death (Kern et al.) . Detailed genetic analysis has shown there are deletions of alleles from each possible chromosomal arm in at least some of the colon tumors, raising the possibility there are yet to be identified tumor suppressor genes.
Advances in cancer therapy were also a substantial focus of the meeting. In a joint symposium with ASCO, the biology and clinical applications of hematopoietic growth factors were discussed. Clinical trials with G-CSF, GM-CSF and erythropoietin continue to move forward, and these factors will likely have roles in cancer chemotherapy in abrogating or accelerating recovery from myelosuppresive treatment, and in conjunction with bone marrow transplantation. Future directions include the use of these factors in combination with those acting on early progenitors, such as interleukin-1 and interleukin-3.
The potential role of DNA topoisomerases as targets of anticancer drug action was discussed at several sessions and a minisymposium. A number of active anticancer drugs, including several that also bind directly to DNA, stabilize the complexx of both topoisomerase I and II with DNA. Topoisomerases alter the supercoiling of DNA by transiently producing single or doublestrand breaks in the DNA. The stabilization of the cleavage complex can be detected as protein-associated DNA strand breaks. An interaction between ongoing DNA synthesis and the cytotoxicity of drug-induced topoisomerase-DNA complexes was reported by Pommier et al. Inhibition of DNA synthesis completely blocked the cytotoxicity of camptothecin (a topo I inhibitor), but only partially protected the cells from etopside and amscarine (topo II inhibitors). The question of how these complexes might lead to the cytotoxic effects was discussed by Dr. Kurt Kohn. It was suggested that a major lethal event may be the encounter of a moving DNA replication fork with a drug-stabilized topoisomerase complex.
The importance of drug resistance to the use of cancer chemotherapeutic agents was underscored by the over 75 papers presented on this topic. The gene responsible for the multidrug resistance phenotype encodes P-glycoprotein, a membrane-spanning high molecular weight glycoprotein with amino acid homology to bacterial transport protein. The multidrug resistance gene mdr-1 was reported to span over 100 kb of DNA and contain 28 introns (Chen et al.) . Using the highly sensitive technique of polymerase chain reaction, expression of mdr-1 was detected in multidrug-resistant cell lines. Elevated levels of expression of mdr-2 was detected in tumor-derived cell lines; however high levels of expression of mdr-2 was also seen in several normal human tissues, including liver, kidney, colon and adrenal (Noonan et al.) . The significance of the expression of these genes in normal tissues, and the relationship between expression and the development of resistance in vivo remains to be clarified. Other mechanisms of resistance were also discussed, including the role of glutathione S-transferase in resistance to alkylating agents (Cowan) and the presence in resistant cells of a putative inhibitor of the formation of drug-induced topoisomerase II-DNA complexes (Zwelling et al.) .
